GAVISCON LIQUID PEPPERMINT SUSPENSION

Země: Jihoafrická republika

Jazyk: angličtina

Zdroj: South African Health Products Regulatory Authority (SAHPRA)

Dostupné s:

Reckitt Benckinser Pharmaceuticals (Pty) Ltd

Dávkování:

See ingredients

Léková forma:

SUSPENSION

Složení:

EACH 10 ml SUSPENSION CONTAINS SODIUM ALGINATE 500 mg

Stav Autorizace:

Registered

Datum autorizace:

1997-07-01

Informace pro uživatele

SCHEDULING STATUS: S0
PROPRIETARY NAME, STRENGTH AND DOSAGE FORM:
GAVISCON LIQUID ANISEED SUSPENSION
Sodium alginate 500 mg and Sodium bicarbonate 267 mg per 10 ml
Read this entire leaflet carefully because it contains important
information for you.
This medicine is available without a doctor’s prescription, for you
to treat a mild illness.
Nevertheless, you still need to use GAVISCON LIQUID ANISEED carefully
to get the best results from it.

Keep this leaflet. You may need to read it again

Ask your pharmacist if you need more information or advise.

Do not share Gaviscon Liquid Aniseed with any other person.

You must see a doctor if your symptoms worsen or do not improve after
7 days.
1. WHAT GAVISCON LIQUID ANISEED CONTAINS:
Each 10 ml of GAVISCON LIQUID ANISEED contains sodium alginate 500 mg
and Sodium Bicarbonate 267
mg.
The other ingredients are calcium carbonate carbomer, sodium
saccharin, fennel
flavour, erythrosine, sodium hydroxide and water.
Preservatives: Methylhydroxybenzoate 0,4% m/v and
Propylhydroxybenzoate 0,06% m/v.
Contains sweetener (Saccharin sodium 0,100%m/v).
2. WHAT GAVISCON LIQUID ANISEED IS USED FOR:
GAVISCON LIQUID ANISEED is used for the following conditions: gastric
reflux (reflux of stomach contents
into the oesophagus); reflux oesophagitis (inflamed foodpipe);
heartburn, including heartburn during
pregnancy; and conditions associated with gastric reflux including
hiatus hernia (protrusion of muscle
through a muscle wall); flatulence (accumulation of gas in the stomach
or intestines); epigastric and
retrosternal distress.
3. BEFORE YOU TAKE GAVISCON LIQUID ANISEED
DO NOT TAKE GAVISCON LIQUID ANISEED:

If you are hypersensitive (allergic) to sodium alginate or any other
ingredients.
Contains methyl parahydroxybenzoate and propyl parahydroxybenzoate:
May cause allergic reactions
(possibly delayed)
TAKE SPECIAL CARE WITH GAVISCON LIQUID ANISEED:

If you have heart disease or high blood pressure

If you are receiving corticosteroids

If you have kidney disease

Charakteristika produktu

GAVISCON LIQUID ANISEED L/11.10/1
RECKITT BENCKISER PHARMACEUTICALS (PTY) LTD
Page 1 of 5
SCHEDULING STATUS: [S0]
PROPRIETARY NAME AND DOSAGE FORM:
GAVISCON LIQUID ANISEED Suspension
COMPOSITION:
Each 10 ml of GAVISCON LIQUID ANISEED contains sodium alginate 500 mg
and Sodium
Bicarbonate 267 mg.
The other ingredients are calcium carbonate carbomer, sodium
saccharin, fennel
flavour, erythrosine, sodium hydroxide and water.
Preservatives: Methylhydroxybenzoate 0,4% m/v and
Propylhydroxybenzoate 0,06% m/v.
Contains sweetener (Saccharin sodium 0,100%m/v).
PHARMACOLOGICAL CLASSIFICATION:
A 11.10 Medicines acting on gastro-intestinal tract. Special
combinations.
PHARMACOLOGICAL ACTION:
Pharmacodynamic Properties:
On ingestion sodium alginate and sodium bicarbonate reacts with saliva
and gastric acid to produce a
viscous gel, which floats on the stomach contents suppressing gastric
reflux.
Pharmacokinetic properties:
In severe cases, the gel itself may be refluxed into the oesophagus
where it helps protect the mucosa.
INDICATIONS:
GAVISCON LIQUID ANISEED is indicated for the following conditions:
Gastric reflux, reflux
oesophagitis, heartburn, including heartburn of pregnancy, and
conditions associated with gastric reflux
including hiatus hernia; flatulence; epigastric and retrosternal
distress where the underlying cause is
gastric reflux.
GAVISCON LIQUID ANISEED L/11.10/1
RECKITT BENCKISER PHARMACEUTICALS (PTY) LTD
Page 2 of 5
CONTRA-INDICATIONS:
Hypersensitivity to any of the ingredients.
WARNINGS AND SPECIAL PRECAUTIONS:
Sodium bicarbonate should be administered with caution in patients
with congestive heart failure , renal
impairment and cirrhosis of the liver, hypertension and to patients
receiving corticosteroids, patients
with metabolic or respiratory alkalosis, hypocalcaemia or
hypochlorhydria.
Hypocalcaemia/alkalosis can occur following the regular use of calcium
carbonate.
Care needs to be taken in treating patients with hypercalcaemia,
nephrocalcinosis and recurrent
calcium containing renal calculi.
Contains